The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10969 malaria professionals are enjoying the free benefits of MalariaWorld today

Covid-19

Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic

July 6, 2021 - 14:27 -- Open Access
Author(s): 
Grygiel-Górniak B
Reference: 
Clin Rheumatol. 2021 Jul 3

The majority of the medical fraternity is continuously involved in finding new therapeutic schemes, including antimalarial medications (AMDs), which can be useful in combating the 2019-nCoV: coronavirus disease (COVID-19). For many decades, AMDs have been widely used in the treatment of malaria and various other anti-inflammatory diseases, particularly to treat autoimmune disorders of the connective tissue.

Not Open Access | Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets

July 6, 2021 - 14:15 -- NOT Open Access
Author(s): 
Altable M, de la Serna JM
Reference: 
Virus Res. 2021 Jul 2;299:198347

There is a marked discrepancy between SARS-CoV-2 seroprevalence and COVID-19 cases and deaths in Africa.

Malaria incidence and mortality in Zimbabwe during the COVID-19 pandemic: analysis of routine surveillance data

May 26, 2021 - 09:29 -- Open Access
Author(s): 
Samuel Gavi, Oscar Tapera, Joseph Mberikunashe and Mufaro Kanyangarara
Reference: 
Malaria Journal 2021 20:233, 24 May 2021

The coronavirus disease 2019 (COVID-19) pandemic has posed a unique challenge to health care systems globally. To curb COVID-19 transmission, mitigation measures such as travel restrictions, border closures, curfews, lockdowns, and social distancing have been implemented. However, these measures may directly and indirectly affect the delivery and utilization of essential health services, including malaria services. The suspension of indoor residual spraying (IRS) and insecticide-treated net (ITN) distribution, shortages of malaria commodities, and reduced demand for health services have hindered the continued delivery of malaria services. The overall goal of this analysis was to describe the trends in malaria incidence and mortality in Zimbabwe prior to and during the pandemic to understand the consequences of COVID-19-related changes in the delivery and utilization of malaria services.

Navigating the COVID-19 Crisis to Sustain Community-Based Malaria Interventions in Cambodia

May 19, 2021 - 14:05 -- Open Access
Author(s): 
Feldman M, Vernaeve L, Tibenderana J, Braack L, Debackere M, Thu HK, Hamade P, Lo K
Reference: 
Glob Health Sci Pract. 2021 May 13

Cambodia has made impressive progress in reducing malaria trends and, in 2018, reported no malaria-related deaths for the first time. However, the coronavirus disease (COVID-19) pandemic presents a potential challenge to the country's goal for malaria elimination by 2025. The path toward malaria elimination depends on sustained interventions to prevent rapid resurgence, which can quickly set back any gains achieved.Malaria Consortium supported mobile malaria workers (MMWs) to engage with target communities to build acceptance, trust, and resilience.

World Malaria Day 2021: Commemorating 15 Years of Contribution by the United States President's Malaria Initiative

April 28, 2021 - 14:22 -- Open Access
Author(s): 
Steketee RW, Choi M, Linn A, Florey L, Murphy M, Panjabi R
Reference: 
Am J Trop Med Hyg. 2021 Apr 23:tpmd210432

World Malaria Day 2021 coincides with the 15th anniversary of the United States President's Malaria Initiative (PMI) and follows the first anniversary of the declaration of the coronavirus disease (COVID-19) pandemic. From 2006 to the present, the PMI has led to considerable country-managed progress in malaria prevention, care, and treatment in 24 of the highest-burden countries in sub-Saharan Africa and three countries in the Southeast Asia Greater Mekong subregion.

Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check

April 22, 2021 - 08:29 -- Open Access
Author(s): 
Sharma P, McAlinden KD, Ghavami S, Deshpande DA
Reference: 
Eur J Pharmacol. 2021 Apr 15;897:173928

The recent SARS-CoV-2 pandemic poses one of the greatest challenges to modern medicine. Therefore, identification of new therapeutic strategies seems essential either based on novel vaccines or drugs or simply repurposing existing drugs. Notably, due to their known safety profile, repurposing of existing drugs is the fastest and highly efficient approach to bring a therapeutic to a clinic for any new indication. One such drug that has been used extensively for decades is chloroquine (CQ, with its derivatives) either for malaria, lupus and rheumatoid arthritis.

COVID-19 and Syndemic challenges in 'Battling the Big Three': HIV, TB and malaria

March 31, 2021 - 14:20 -- Open Access
Author(s): 
Velavan TP, Meyer CG, Esen M, Kremsner PG, Ntoumi F
Reference: 
Int J Infect Dis. 2021 Mar 26:S1201-9712(21)00289-7

Indirect effects of the COVID-19 pandemic have the potential to seriously undermine the health system in sub-Saharan Africa with an increase in the incidences of malaria, tuberculosis (TB) and HIV infections.

NOT Open Access | Antimalarial Quinacrine and Chloroquine Lose Their Activity by Decreasing Cationic Amphiphilic Structure with a Slight Decrease in pH

March 30, 2021 - 14:21 -- NOT Open Access
Author(s): 
Kitagawa T, Matsumoto A, Terashima I, Uesono Y
Reference: 
J Med Chem. 2021 Mar 27

Quinacrine (QC) and chloroquine (CQ) have antimicrobial and antiviral activities as well as antimalarial activity, although the mechanisms remain unknown. QC increased the antimicrobial activity against yeast exponentially with a pH-dependent increase in the cationic amphiphilic drug (CAD) structure. CAD-QC localized in the yeast membranes and induced glucose starvation by noncompetitively inhibiting glucose uptake as antipsychotic chlorpromazine (CPZ) did.

NOT Open Access | Does hydroxychloroquine still have any role in the COVID-19 pandemic

March 17, 2021 - 16:58 -- NOT Open Access
Author(s): 
Schilling WH, White NJ
Reference: 
Expert Opin Pharmacother. 2021 Mar 16:1-10

The 4-aminoquinolines, chloroquine, and hydroxychloroquine have been used for over 70 years for malaria and rheumatological conditions, respectively. Their broad-spectrum antiviral activity, excellent safety profile, tolerability, low cost, and ready availability made them prime repurposing therapeutic candidates at the beginning of the COVID-19 pandemic.

Pregnancy and COVID-19: Do not overlook malaria

March 17, 2021 - 09:33 -- Open Access
Author(s): 
Papaccio M, Castellani R, Zanardini C, Sartori E, Prefumo F, Saccani B.
Reference: 
Int J Gynaecol Obstet. 2021 Mar 13

The synchronous co-infection of malaria and SARS-CoV-2 in pregnancy has recently been reported [1]. A 38-year-old woman born in Burkina Faso, gravida 4 para 3, lived in Italy for 8 years until November 2019 when she returned to Burkina Faso for a short visit.

Pages

Subscribe to RSS - Covid-19